Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.
2.

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH.

Blood. 2009 Jun 11;113(24):6161-71. doi: 10.1182/blood-2008-10-187138. Epub 2009 Apr 16.

3.

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH.

Blood. 2008 Feb 15;111(4):2211-9. Epub 2007 Nov 19.

4.

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH.

Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988. Epub 2012 Jan 23.

5.

What signals are generated by anti-CD20 antibody therapy?

Bonavida B.

Curr Hematol Malig Rep. 2006 Dec;1(4):205-13. doi: 10.1007/s11899-006-0001-z. Review.

PMID:
20425315
6.

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.

Rossi EA, Chang CH, Goldenberg DM.

PLoS One. 2014 May 19;9(5):e98315. doi: 10.1371/journal.pone.0098315. eCollection 2014.

7.

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Shan D, Ledbetter JA, Press OW.

Cancer Immunol Immunother. 2000 Mar;48(12):673-83.

PMID:
10752475
8.

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.

Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT.

Cancer Immunol Immunother. 2011 Jun;60(6):771-80. doi: 10.1007/s00262-011-0978-6. Epub 2011 Feb 24.

9.

Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.

Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B.

Int J Oncol. 2009 Dec;35(6):1289-96.

PMID:
19885551
10.

Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH.

Cancer Res. 2008 Oct 15;68(20):8384-92. doi: 10.1158/0008-5472.CAN-08-2033.

11.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

12.
13.

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.

Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH.

Blood. 2009 Jan 29;113(5):1062-70. doi: 10.1182/blood-2008-07-168146. Epub 2008 Oct 21. Erratum in: Blood. 2009 May 21;113(21):5368.

14.

Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).

Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.

Clin Cancer Res. 2008 Oct 1;14(19):6154-60. doi: 10.1158/1078-0432.CCR-08-0404.

15.

Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.

Zhang H, Song L, Ye H, Hu L, Liang W, Liu D.

Cell Physiol Biochem. 2013;32(3):645-54. doi: 10.1159/000354468. Epub 2013 Sep 10.

PMID:
24022075
16.

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.

17.

The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.

Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B.

Int J Oncol. 2011 Jun;38(6):1683-94. doi: 10.3892/ijo.2011.984. Epub 2011 Mar 23.

PMID:
21455568
18.

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.

Chang CH, Wang Y, Gupta P, Goldenberg DM.

MAbs. 2015;7(1):199-211. doi: 10.4161/19420862.2014.979081.

19.
20.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
Items per page

Supplemental Content

Write to the Help Desk